In vitro studies have shown that primary CML patient cells treated with asciminib and ponatinib had decreased BCR::ABL1 activity and colony formation when compared to those treated with asciminib monotherapy [43]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.